Anuh Pharma board meeting update: results, dividend 2026

What the latest corporate updates indicate

Anuh Pharma Ltd (BSE: 506260) has continued to issue exchange filings around its board meetings, financial results, corporate actions, and trading window compliance. The company’s disclosures include multiple board meeting intimations for unaudited results during FY2025-26, and earlier decisions around audited FY2024-25 results. Separately, the company also indicated that its board would review audited FY2025-26 results, consider a dividend, and finalise the AGM notice, along with trading window updates.

For investors tracking the stock through the results calendar, these filings help map when financial numbers are expected and what shareholder actions are on the agenda. The updates also capture key dates such as record dates for dividend and bonus shares, and the Annual General Meeting schedule previously announced for August 2025.

Board meeting scheduled on 6 February 2026

In a board meeting intimation filed with BSE, Anuh Pharma said its board meeting is scheduled on 06/02/2026. The intimation stated the meeting would consider and approve unaudited financial results along with a limited review report. The filing references consideration of results for the quarter and half year ended 30 September 2025.

While the headline line also mentions “unaudited financial results for the quarter ended 31st December, 2025,” the detailed description in the provided text specifically refers to the quarter and half-year ended 30 September 2025. Investors typically rely on the final filed outcome and the attached financial statements for clarity on the exact period covered.

Earlier board meetings for unaudited results in FY2025-26

The company had earlier informed BSE that a board meeting was scheduled on 07/11/2025 to consider and approve unaudited financial results for the quarter and half year ended 30 September 2025. It also said the board may consider any other matter with the permission of the chairman.

For the June quarter cycle, Anuh Pharma informed BSE that a board meeting was scheduled on 08/08/2025 to consider and approve unaudited financial results for the quarter ended 30 June 2025. The company’s disclosures around this period also refer to the appointment of a Chief Marketing Officer being included in the agenda.

Newspaper publication disclosures

Anuh Pharma also disclosed newspaper publications of its unaudited financial results. For the quarter and half year ended 30 September 2025, the results were published in Financial Express (English) and Mumbai Lakshdeep (Marathi) on 09 November 2025.

For the quarter ended 30 June 2025, the company disclosed that unaudited results were published in Financial Express (English) and Mumbai Lakshdeep (Marathi) on 09 August 2025. These disclosures typically form part of listing compliance and provide an additional public record of financial reporting.

FY2024-25 audited results: dividend and bonus issue decisions

For FY2024-25, Anuh Pharma’s board meeting on 23/05/2025 considered and approved audited financial results for the quarter and financial year ended 31 March 2025. Alongside the results, the board approved a bonus issue and proposed a final dividend, both subject to shareholder approvals.

The company’s filings state the board considered and approved an issue of bonus equity shares in the ratio 1:1. This means 1 equity share of face value INR 5 for every 1 fully paid-up equity share of face value INR 5 held as on the record date. The bonus issue was stated to be subject to shareholders’ approval via postal ballot.

Dividend details and revised record date

Anuh Pharma recommended a final dividend of INR 1.50 per equity share on post-bonus share capital for the financial year ended 31 March 2025. The filing describes this as a 30% payout on the face value of INR 5 each, and notes that bonus shares would also be entitled to the proposed final dividend of INR 1.50 per share.

A BSE corporate action table in the provided text shows: announcement date 23 May 2025, ex-date 14 Aug 2025, and record date 15 Aug 2025 for the final dividend. The company also stated this was a revised record date as per a BSE announcement dated 29/07/2025.

AGM schedule and book closure period

The disclosures in the provided text state that the company’s 65th Annual General Meeting was scheduled for Friday, 22 August 2025. The company also stated that the revised record date would be used for determining shareholder eligibility for the dividend (if declared and approved at the AGM) and for voting eligibility through remote e-voting or at the AGM.

The text also includes a stated book closure period: the Register of Members and Share Transfer Books would remain closed from 16th August to 22nd August 2025 (both days inclusive) for AGM and dividend purposes, if approved by members.

Bonus issue details: shares, amount, and reserves

The bonus issue section in the provided text includes operational specifics. It states that 5,01,12,000 equity shares of INR 5 each were proposed to be issued, with an approximate total amount of INR 25,05,60,000, which is INR 25.06 crore.

The text further states that free reserves required for implementing the bonus issue were INR 25.06 crore, and that free reserves were INR 300.85 crore. It also states the estimated timeline for credit or dispatch of bonus shares was “within 2 months from the date of board approval.”

Trading window closure disclosure

The company disclosed that the trading window for dealing in securities of the company would remain closed from Tuesday, 01 April 2025 till the expiry of 48 hours after the declaration of audited financial results for the year ended 31 March 2025. This aligns with standard insider trading compliance practice around price-sensitive financial announcements.

Financial performance snapshot: Q4FY25 and FY25

Anuh Pharma’s Q4FY25 numbers in the provided text show profit pressure despite higher sales. Net profit fell 18.88% year-on-year to INR 12.46 crore in the March 2025 quarter from INR 15.36 crore in the March 2024 quarter.

Sales increased 20.90% year-on-year to INR 198.14 crore in Q4FY25 compared to INR 163.89 crore in Q4FY24. EBITDA decreased 8.98% to INR 20.07 crore in Q4FY25 from INR 22.05 crore in Q4FY24.

For the full year, net profit declined 21.16% to INR 47.35 crore in FY25 from INR 60.06 crore in FY24. Sales increased 2.24% to INR 661.51 crore in FY25 compared to INR 647.00 crore in FY24.

Balance sheet data disclosed with FY25 results

Along with the audited FY25 outcome, the provided text states that total assets as of March 31, 2025 were INR 50,662.77 lakhs, which is INR 506.63 crore. The text describes this as showing significant growth from the previous year, without specifying the prior-year assets figure.

Stock price snapshot from the provided feed

The provided market feed shows end-of-day snapshots around 12:51 on 09-12-2025. BSE EOD is shown at INR 79.90 and NSE EOD is shown at INR 79.25, based on the text provided.

Key facts table

Financial highlights table (INR crore)

Why these disclosures matter for shareholders

The filings combine near-term reporting schedules with shareholder-action items. Board meeting intimations create a timetable for when limited-reviewed numbers may be released, while corporate action disclosures set expectations on dividend eligibility dates and bonus-share timelines.

The FY25 disclosures also show how the company balanced shareholder returns with financial performance trends. Sales rose in both Q4FY25 and FY25, but net profit and EBITDA declined in the periods disclosed, which is information investors commonly monitor alongside dividend decisions.

Conclusion

Anuh Pharma’s exchange filings outline a steady flow of board activity around unaudited results during FY2025-26, and earlier FY25 decisions that included a proposed INR 1.50 per share dividend and a 1:1 bonus issue. The next milestones for investors are the outcomes filed after the scheduled board meeting dates and any subsequent updates on shareholder approvals, record dates, and result publications disclosed to exchanges.